Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Delmar

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2013
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinomaJean-Pierre Delord, Josep Tabernero, Rocío García-Carbonero, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentGregory Klein, Gil D Rabinovici, Henrik Zetterberg, et al.
Journal of Alzheimer'S Disease : JAD|May 28, 2017
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)Stephane Nave, Rachelle S Doody, Mercè Boada, et al.
Eclinicalmedicine|March 20, 2026
Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosisMargaux Poleur, Barbara Willekens, Bertrand Degos, et al.
The New England Journal of Medicine|November 15, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's DiseaseRandall J Bateman, Janice Smith, Michael C Donohue, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2024
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2013
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinomaJean-Pierre Delord, Josep Tabernero, Rocío García-Carbonero, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentGregory Klein, Gil D Rabinovici, Henrik Zetterberg, et al.
Journal of Alzheimer'S Disease : JAD|May 28, 2017
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)Stephane Nave, Rachelle S Doody, Mercè Boada, et al.
Eclinicalmedicine|March 20, 2026
Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosisMargaux Poleur, Barbara Willekens, Bertrand Degos, et al.
The New England Journal of Medicine|November 15, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's DiseaseRandall J Bateman, Janice Smith, Michael C Donohue, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2024
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 5